Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences